Lucentisranibizumab
According to the FDA label: LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema…
26,148 adverse event reports submitted to the FDA (2005–2026)
Top Reported Adverse Events
The most frequently reported events in association with Lucentis in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Death 3,790 reports
A report that the person died. A death appearing in reports for a drug does not mean the drug caused it. Reports record that a death occurred while the medication was being used, which can happen for many unrelated reasons.
Full definition in the glossary →Visual Acuity Reduced 2,888 reports
A decrease in the sharpness of vision.
Full definition in the glossary →Off Label Use 1,681 reports
Using a medication for a condition or in a way that the FDA has not officially approved. This is common and often legal, and a report of it does not mean something went wrong. Doctors sometimes prescribe drugs off label based on their judgment.
Full definition in the glossary →Visual Impairment 1,620 reports
Reduced ability to see.
Full definition in the glossary →Cerebrovascular Accident 1,237 reports
The medical term for a stroke, which happens when blood flow to part of the brain is interrupted.
Full definition in the glossary →Drug Ineffective 1,199 reports
A report that the medication did not work as expected for the person taking it. This is a reporting category, not a sign the drug is defective. It simply means someone felt it was not helping their condition.
Full definition in the glossary →- Blindness 1,040 reports
- Eye Haemorrhage 1,040 reports
Vision Blurred 1,030 reports
A loss of sharpness in vision, making things look out of focus.
Full definition in the glossary → See all drugs reporting this event →No Adverse Event 1,022 reports
A report that was filed but did not actually describe any adverse event. This is a record-keeping category.
Full definition in the glossary →Eye Pain 955 reports
Pain in or around the eye.
Full definition in the glossary →- Retinal Haemorrhage 792 reports
- Endophthalmitis 722 reports
Myocardial Infarction 689 reports
The medical term for a heart attack.
Full definition in the glossary →Cataract 679 reports
A clouding of the lens of the eye that can blur vision.
Full definition in the glossary →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Female | 12,765 |
| Male | 9,959 |
| Unknown | 210 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 76 |
| 18-34 | 164 |
| 35-49 | 545 |
| 50-64 | 2,155 |
| 65-74 | 2,954 |
| 75+ | 6,672 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Lucentis. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Other Serious | 14,157 |
| Death | 5,085 |
| Hospitalization | 4,783 |
| Non-Serious | 3,836 |
| Disability | 809 |
| Life-Threatening | 448 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Lucentis. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 52 |
| 2007 | 563 |
| 2008 | 351 |
| 2009 | 691 |
| 2010 | 1,150 |
| 2011 | 2,457 |
| 2012 | 2,383 |
| 2013 | 2,727 |
| 2014 | 2,172 |
| 2015 | 1,268 |
| 2016 | 1,251 |
| 2017 | 2,543 |
| 2018 | 1,575 |
| 2019 | 1,286 |
| 2020 | 1,266 |
| 2021 | 1,039 |
| 2022 | 853 |
| 2023 | 748 |
| 2024 | 1,232 |
| 2025 | 458 |
| 2026 (partial) | 82 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Lucentis
In FDA adverse event reports that mention Lucentis, these medications appeared most often in the same report.
- Bevacizumab (2,420 reports)
- Aflibercept (1,482 reports)
- Aspirin (1,153 reports)
- Furosemide (703 reports)
- Simvastatin (696 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026